VERADERMICS INC (MANE)
Health Care · Aesthetic and dermatological biopharmaceuticals · NYSE
VeraDermics is a clinical-stage biotech developing an oral, extended-release minoxidil formulation (VDPHL01) to address the 80 million Americans with pattern hair loss who lack effective, convenient, non-hormonal treatment options.
What VERADERMICS INC does
VeraDermics is a dermatologist-founded, late-stage clinical biopharmaceutical company developing innovative therapeutics for aesthetic and dermatological conditions, with an initial focus on pattern hair loss (PHL). The company's lead candidate, VDPHL01, is an oral, extended-release formulation of minoxidil designed as a non-hormonal treatment for both men and women with PHL, addressing limitations of current therapies including slow onset, inconsistent results, tolerability issues, and lack of FDA-approved oral options for women.
Themes: ["Pattern hair loss / hair restoration","Aesthetic dermatology","Oral pharmaceutical formulations","Clinical-stage biopharmaceuticals"]
Fundamentals
- Price$124.91 as of 2026-07-09 close
- Market cap$4.9B as of 2026-07-10
- 1-year return+213.2% as of 2026-07-09 close
- ROE-48.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta-0.77 as of 2026-07-10
Key risks (from latest filing)
["Clinical trial execution risk: company's regulatory pathway depends on successful completion of three pivotal registration-directed Phase 2/3 and Phase 3 trials in male and female patient populations; delays or unfavorable data could materially impact FDA approval timelines","Cardiac safety risk: while VDPHL01 is designed to minimize cardiac activity versus IR oral minoxidil, any cardiac-related adverse events in ongoing or completed trials could jeopardize regulatory approval or market adoption","Competition and market adoption: established topical and off-label oral minoxidil treatments, as well as potential competing therapies in development, may limit market opportunity despite VDPHL01's intended advantages in convenience and tolerability"]
Competitors & peers
- Allergan (aesthetic/dermatology)
- Galderma (dermatology)
- Hims & Hers (telehealth/hair loss services)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.